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ABSTRACT
Objectives: GH therapy is still controversial, except in severe GH deficiency (SGHD). The objective of 
this study was to compare the response to growth hormone (GH) therapy in children with partial GH 
insensitivity (PGHIS) and mild GH deficiency (MGHD) with those with SGHD. Subjects and metho-
ds: Fifteen PGHIS, 11 MGHD, and 19 SGHD subjects, followed up for more than one year in the Bra-
zilian public care service, were evaluated regarding anthropometric and laboratory data at the begin-
ning of treatment, after one year (1st year) on treatment, and at the last assessment (up to ten years 
in SGHD, up to four years in MGHD, and up to eight years in PGHIS). Results: Initial height standard 
deviation score (SDS) in SGHD was lower than in MGHD and PGHIS. Although the increase in 1st 
year height SDS in comparison to initial height SDS was not different among the groups, height-SDS 
after the first year of treatment remained lower in SGHD than in MGHD. There was no difference in 
height-SDS at the last assessment of the children among the three groups. GH therapy, in the entire 
period of observation, caused a trend towards lower increase in height SDS in PGHIS than SGHD but 
similar increases were observed in MGHD and SGHD. Conclusion: GH therapy increases height in 
PGHIS and produces similar height effects in MGHD and SGHD. Arq Bras Endocrinol Metab. 2014;58(1):23-9
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RESUMO
Objetivos: O tratamento com GH é ainda controverso, salvo na deficiência grave de GH (SGHD). O 
objetivo deste estudo foi comparar a resposta ao tratamento com GH em indivíduos com insensi-
bilidade parcial ao GH (PGHIS) e na deficiência moderada do GH (MGHD) com SGHD. Sujeitos e 
métodos: Quinze pacientes com PGHIS, 11 com MGHD e 19 com SGHD, seguidos por mais de um 
ano no Sistema Único de Saúde, foram avaliados antropométrica e laboratorialmente, no início, com 
um ano de tratamento e na última avaliação (tempo máximo de dez anos na SGHD, quatro anos na 
MGHD e oito anos na PGHIS). Resultados: O escore de desvio-padrão (EDP) da estatura inicial foi 
menor nos indivíduos com SGHD do que naqueles com MGHD e PGHIS. Embora o aumento no EDP 
da estatura no primeiro ano em comparação com o inicial não fosse diferente entre os grupos, o EDP 
da altura no primeiro ano de tratamento permaneceu menor na SGHD que na MGHD. Não houve 
diferença no EDP da estatura na última avaliação entre os três grupos. O tratamento com GH, no 
período completo da observação, provocou uma tendência a menor aumento no EDP da estatura 
nos pacientes com PGHIS que naqueles com SGHD, entretanto aumentos semelhantes foram en-
contrados nos grupos MGHD e SGHD. Conclusão: O tratamento com GH aumentou a estatura nos 
indivíduos com PGHIS e produziu efeitos similares na estatura em MGHD e SGHD. Arq Bras Endocrinol 
Metab. 2014;58(1):23-9
Descritores
Baixa altura idiopática; tratamento com hormônio do crescimento; deficiência de hormônio do crescimento; insensibilidade 
parcial ao GH 
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InTRODUCTIOn
Growth hormone (GH) has been used to treat chil-dren with GH deficiency (GHD) since 1958. Due 
to the poor supply, the use of GH extracted from cada-
veric pituitaries was limited to severe GHD (SGHD). 
In order to ensure treatment for children who needed 
it mostly, a GH stimulation test peak less than 5 ng/mL 
was required to initiate GH therapy. In 1985, after the 
description of four cases of Creutzfeldt-Jakob disea se, 
recombinant human GH (rhGH) replaced cadaveric 
GH in the treatment of GHD (1,2). The unlimited 
production of rhGH allowed the offer of the treat-
ment to more children, and the GH peak cutoff va-
lue during the stimulation test was increased to 7 ng/
mL, and finally to 10 ng/mL). The Food and Drug 
Administration (FDA) approved the use of rhGH for 
GHD children and adults, and subsequently to chro-
nic renal failure, Turner syndrome, AIDS cachexia, 
Prader-Willi syndrome, children born small for gesta-
tional age (SGA), idiopathic short stature (ISS), short 
bowel syndrome, Noonan syndrome and SHOX Dele-
tion (3-5). 
A GH concentration of 10 ng/mL determined 
by radioimmunoassay is equivalent to 7 ng/mL in 
monoclonal assays (6,7). Children with height of two 
or more standard deviations (SDs) below the mean for 
chronological age and sex in the absence of an identified 
cause  are classified as ISS (5,8). There is a group of short 
children who exhibit high response to pharmacological 
tests (GH peak ≥ 40 mU/L or 18 ng/mL), with low or 
normal insulin-like growth factor-I (IGF-I) levels, that 
are considered by some authors as having partial GH 
insensitivity (PGHIS), with a potential responsiveness 
to higher dose of rhGH (9-12). However, it is not a 
consensus, and it is rather arguable.
Since 2010, in Brazil, with the current laboratory 
methods of chemiluminescence and fluorometry, the GH 
peak level required by the Health System to provide GH 
treatment for GHD children is less than 5 ng/mL (13). 
This demand excludes from treatment children with GH 
peak between 5 and 10 ng/mL, which might have mild 
GH deficiency (MGHD), as well as those with possible 
PGHIS. However, some children possibly bearing 
MGHD or PGHIS were treated in the public health care 
system in northeastern Brazil, in the state of Sergipe, 
before this law was determined. The assessment of GH 
therapy response in both groups can be very helpful 
and provide better understanding of the underlying 
process. This prompted us to compare the response to 
GH therapy in patients with MGHD and PGHIS with 
that observed in a group of children with severe GH 
deficiency (SGHD), in a preliminary attempt to analyze 
the usefulness of such approach in a public scenario.
SUBJECTS AnD METHODS
Subjects
In a retrospective study, medical records of 86 children 
were analyzed. The records came from the Endocri-
nology Division of the University Hospital of Fede-
ral University of Sergipe, Brazil, who had used rhGH 
(HORMOTROP® AQ, Dong – A Pharmaceutical Co. 
Ltd, South Korea). GH dose was 30 µg/kg/day in se-
vere GH deficiency, and 50 µg/kg/day in other condi-
tions. Inclusion criteria were patients with short stature 
and serum IGF-I concentration below the mean for 
chronological age and gender, who had received GH 
therapy for at least one year. All of them had undergone 
stimulation test (clonidine or insulin hypoglycemia) 
and GH were measured by chemiluminescence (GH 
ICMA Immulite, Diagnostic Products Corporation, 
Los Angeles, CA) or fluorometric assays (Auto Delfia, 
Wallac, Turku, Finland). Exclusion criteria were incom-
plete medical records (n = 12), Turner syndrome (n = 
10), chronic renal failure (n = 1), concomitant use of 
GnRH analogue treatment for central precocious pu-
berty (n = 2), chronic disease, corticosteroid treatment, 
dysmorphic syndromes (n = 3), SGA (n = 4), and GH 
peak between 10 and 18 ng/mL (n = 9). Therefore, 45 
children were selected for the study. 
Subjects were arbitrarily classified according to GH 
peak in: a) PGHIS: GH peak ≥ 18 ng/mL, n = 15, 10 
boys; b) MGHD: GH peak ≥ 5 and < 10 ng/mL, n = 
11, 7 boys; and c) SGHD: GH peak < 5 ng/mL, n = 
19, 10 boys. Seven individuals from this latter group 
had multiple pituitary deficits. 
The study was approved by the Ethical Committee 
of Federal University of Sergipe and written consent 
was obtained from the guardians of all participants 
before enrolling them in the study. 
Assessed variables and study design
Data on chronological age (CA), height, weight, body 
mass index (BMI), growth velocity (GV), pubertal 
stage, IGF-I levels and bone age (BA) were collected 
GH in mild GHD or partial GH-IGF insensitivity
Co
py
rig
ht
©
 A
BE
&
M
 to
do
s o
s d
ire
ito
s r
es
er
va
do
s.
25 Arq Bras Endocrinol Metab. 2014;58/1
in 3 moments from the medical records: just before 
starting rhGH (initial) treatment, after 1 year on rhGH 
therapy (first year), and at the last medical record 
(present), after 3.15 (2.77) years on treatment, range 1 
to 10 years in SGHD, 2.42 (1.12) years; range 1 to 4 
years in MGHD, 2.01 (1.71) years; range 1 to 8 years 
in PGHIS. Data regarding rhGH doses, duration of 
treatment and parents’ height were also obtained. Mid-
parental height (MPH) was calculated by the mean 
difference of the father and mother height, corrected 
by 13 cm according to the gender of the child. IGF-I 
was measured by the immunoradiometric assay, with 
double extraction and assay sensitivity of 0.8 ng/mL 
(Diagnostic Systems Laboratories, Inc., Webster, TX). 
The intra- and interassay variabilities were 2.3 and 
2.6%, respectively. 
Statistical analysis
Height and BMI were converted to standard deviation 
scores (SDS) for chronological age using the British 
data as the reference (14). Mid-parental height (MPH) 
was calculated by the mean of the father and mother 
height, corrected by 13 cm according to the child 
gender. Serum IGF-I SDS was calculated according to 
the data provided by the manufacturer for chronological 
age and gender. Variations (∆) in Height-SDS, Weight-
SDS, BMI-SDS, IGF-I-SDS, and BA between initial 
and present evaluations were calculated for each group. 
Data with normal distribution are presented as means 
(standard deviations). Data without normal distribution 
are presented as medians (interquartile ranges). One-way 
ANOVA with Bonferroni post-hoc test was used to compare 
variables among the three groups (SGHD, MGHD e 
PGHIS), and paired t test was used to compare the initial 
and present doses within each group. Fisher’s test was 
used to analyze the distribution pattern of pubertal stages 
in the groups. MANCOVA and ANCOVA were used 
to analyze possible influence of confounder variables in 
initial height SDS, 1st year height SDS, and present height 
SDS, and in ∆ Height SDS, respectively. Statistical analysis 
was performed in the software SPSS/PC 18.0 (SPSS Inc, 
Chicago II). Probability values ≤ 0.05 were considered 
statistically significant. 
RESULTS  
As expected the GH peak were different among the 
3 groups (p = 0.02). GH peak in the SGHD group 
2.0 (1.4) ng/mL, was lower than in MGHD 7.1 (1.4) 
ng/mL (p < 0.0001), and PGHIS group 24.5 (7.7) 
ng/mL (p < 0.0001). 
There were no differences in age or MPH values 
among the groups (Table 1). There was no difference 
in the frequency of pubertal individuals between SGHD 
(6/16) and MGHD group (5/9), but between SGHD 
and PGHIS (11/15, p = 0.003). No difference was 
found in the frequency of pubertal individuals between 
MGHD and PGHIS.
Table 1 also shows the initial, first year, and present 
anthropometric parameters of SGHD, MGHD, and 
PGHIS groups. Initial height-SDS was lower in SGHD 
than in MGHD (p < 0.01) and PGHIS (p < 0.001) 
groups. No difference was found in initial height-SDS 
between MGHD and PGHIS. The increase in 1st year 
height SDS in comparison to initial height SDS was 
not different between the groups, SGHD 0.49 (0.57), 
MGHD 0.51 (0.62), and GHPIS 0.21 (0.25). Height-
SDS after the first year of treatment was still lower in 
SGHD than in MGHD (p = 0.03), but no difference was 
found at the last assessment (present) of the children. 
The significant difference between MPH SDS and initial 
height SDS between SGHD and PGHIS (p = 0.019) 
disappeared in the first year and at the last assessment. 
Table 2 shows the initial, first year and present 
IGF-I levels, bone age, and GH doses of the three 
groups. Initial IGF-I SDS was lower in SGHD than in 
PGHIS (p = 0.001), but no difference was observed 
in initial IGF-I SDS between SGHD and MGHD or 
MGHD and PGHIS. First year and present IGF-I 
SDS were similar in the three groups. GH doses were 
similar, except in the first year when they were higher in 
PGHIS than in SGHG (p = 0.026) (Table 2).
Table 3 shows the variation in height-SDS, IGF-I 
SDS, and BA between the initial and present moments. 
GH therapy brought a lower increase in IGF-I SDS (p 
= 0.03), and a trend towards a lower increase in height 
SDS (p = 0.07) in PGHIS than in SGHD, while similar 
results were observed in MGHD and SGHD. 
MANCOVA using initial height SDS, 1st year height 
SDS, and present height SDS as dependent variables, 
group as factor, and initial age, initial GH dose, duration 
of treatment and pubertal stage (defined as pubertal or 
non-pubertal) as cofactors, revealed that only duration 
of treatment had a significant effect (p = 0.001) of 
0.469 (partial eta squared) with an observed power 
of 0.973. The model explained 51.7% (adjusted R 
squared) of the variability in these variables. ANCOVA 
using the ∆ Height SDS as dependent variable, group 
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GH in mild GHD or partial GH-IGF insensitivity
Table 1. Initial, first year (1st), and present anthropometric parameters, and mid-parental height (MPH) of severe GH deficiency (SGHD), moderate GH 
deficiency (MGHD), and partial insensitivity to GH (PGHIS). Present assessment was done after 3.15 (2.77) years on treatment; range 1 to 10 years in 
SGHD, 2.42 (1.12); range 1 to 4 years in MGHD, 2.01 (1.71) years; range 1 to 8 years old in PGHIS. Data are expressed as means (standard deviations) 
except for the initial present height in SGHD and MGHD and first year height in MGHD, which are expressed as medians (interquartile ranges) 
SGHD MGHD PGHIS
Initial age (years) 10.8 (3.5) 10.7 (2.5) 11.9 (2.5)
Pubertal stage
I (n) 10 4  4
II (n) 1 3  5
III (n) 3 2  5
IV (n) 2  -  1
Initial height SDS -3.33 (1.37) -2.14 (0.54)* -2.15 (0.91)** 
1st year height SDS -2.92 (1.54) -1.62 (0.83)* -2.09 (1.03)  
Present height SDS -2.02 (1.20) -1.28 (1.02) -1.58 (1.01)
MPH SDS -1.46 (1.06) -1.27 (0.88) -1.32 (0.62)
Initial height SDS – MPH SDS -1.87 (1.37) -0.94 (0.93) -0.76 (0.80)*
1st year height SDS – MPH SDS -1.39  (1.34) -0.43 (1.05) -0.57 (0.89)
Present height SDS – MPH SDS - 0.56 (1.07) -0.08 (1.11) -0.19 (0.87)
Initial SDS BMI -0.68 (1.33) 0.29 (1.01) -1.16 (1.29)
1st year SDS BMI -0.69 (2.22) 0.61 (1.60)  -1.16 (1.03)  
Present BMI SDS -0.16 (1.44) 0.21 (1.07) -0.73 (1.27)
Initial growth velocity (cm/year) 3.51 (1,10) 3.47 (0.92) 4.27 (1.13)
1st year growth velocity (cm) 7.43 (3.59) 8.42 (4.50) 6.99 (2.62)
Present velocity (cm/year) 6.93 (3.06) 6.10 (2.31) 6.98 (2.92)
SDS: standard deviation score; * p < 0.05 and ** p < 0.01 compared with SGHD group.
Table 2. Initial, first year and present IGF-I levels, bone age (BA), difference between BA and chronological age (CA), treatment period and GH doses used 
in severe the GH deficiency (SGHD), moderate GH deficiency (MGHD), and partial insensitivity to GH (PGHIS) group. Data are expressed as means (standard 
deviations), except for present BA and initial dose in SGHD, which are expressed as medians (interquartile ranges). GH doses represent yearly intervals. 
GH doses represent yearly intervals. Present assessment was done after 3.15 (2.77) years on treatment, range 1 to 10 years in SGHD, 2.42 (1.12); range 
1 to 4 years old in MGHD, 2.01(1.71) years; range 1 to 8 years in PGHIS
Variables     SGHD MGHD      PGHIS
Initial IGF-I SDS                      -2.12 (0.65) -1.58 (0.71)  -1.11 (0.71)**
1st year IGF-I SDS -1.16 (2.06) -0.24 (1.51) -0.51 (1.31)
Present IGF-I SDS 0.17 (1.41) 0.20 (1.31) -0.22 (1.59)
Initial BA (years) 8.10 (3.32) 9.50 (3.10) 11.51 (2.34)*
1st year BA (years) 10.32 (2.35) 10.80 (2.28) 12.33 (2.88)
Present BA (years) 12.00 (4.13) 13.62 (1.76) 13.06 (1.93)
Initial CA-BA (years) 3.04 (2.70) 1.28 (1.31) 1.41 (2.0)
1st year CA-BA (years) 2.12 (1.81) 2.17 (1.66) 1.99 (2.05)
Present CA-BA (years) 3.5 (2.32) 1.62 (1.84) 2.14 (1.48)
Initial dose (µg/kg/day) 47.36 (13.90) 50.00 (12.29) 51.53 (7.40)
1st year dose (µg/kg/day) 45.55 (9.56) 50.30 (11.78) 57.33 (9.78)*
Present dose (µg/kg/day) 49.61 (12.90) 56.00 (16.08) 56.22 (9.82) 
Treatment period (years) 3.1 (2.8) 2.4 (1.1) 2.0 (1.0)
SDS: standard deviation score; * p < 0.05 and ** p < 0.01 compared with SGHD group.
as factor, and initial age, initial GH dose and pubertal 
stage as cofactors, revealed that group and initial GH 
dose had significant effects (p = 0.001) of 0.339 and 
(p = 0.027) of 0.143 with observed power of 0.943 and 
0.611, respectively. This model explained 47.1% of the 
variability in this variable (adjusted R squared). 
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Table 3. Variation of Height-SDS (∆ Height-SDS), of BMI-SDS (∆ BMI-SDS), of IGF-I-SDS (∆ IGF-I-SDS), of Bone Age (∆ BA) in years, and of the difference 
between Chronological Age (CA) and Bone Age (∆ CA-BA) from the initial to the present assessment in severe GH deficiency (SGHD), moderate GH 
deficiency (MGHD) and partial insensitivity to GH-IGF-I (PGHIS). Data are expressed as means (standard deviations). Present assessment was done after 
3.15 (2.77) years on treatment, range 1 to 10 years in SGHD, 2.42 (1.12) years; range 1 to 4 years in MGHD, 2.01(1.71) years; range 1 to 8 years in PGHIS
Variables     SGHD MGHD      PGHIS
∆ Height SDS 1.30 (1.22) 0.81(0.85) 0.54 (0.50)
∆ BMI SDS 0.51 (0.99) -0.01 (0.88) 0.41 (1.13)
∆ IGF-I SDS 2.42 (1.40) 2.25 (1.08) 1.04 (1.31)*
∆ BA (years) 4.91 (3.41) 3.71 (1.49) 1.50 (1.17)*
∆ CA-BA (years) 1.04 (1.33) 0.48 (0.68) 0.95 (1.29)
SDS: standard deviation score; * p < 0.05 compared with SGHD group.
DISCUSSIOn
The main finding of this study was that, despite the 
higher initial height SDS of MGHD and PGHIS 
children in comparison to SGHD, they presented 
substantial height gain with present height SDS close 
to MPH SDS, probably due to the increase in IGF-I 
SDS in the three groups. While MGHD and SGHD 
behave similarly in response to rhGH therapy, a lower 
increase in IGF-I SDS was found in PGHIS compared 
to SGHD. The lower increase in IGF-I levels could, 
at least in part, explain the trend towards the small 
increase in height SDS observed in PGHIS group 
compared to SGHD. 
Besides the historical GH indication to SGHD, 
nowadays, GH is indicated for nine non-GH deficient 
conditions, including ISS (3,4,15,16). ISS is a condi-
tion where individuals have SDS height less than -2, 
without evidence of endocrine, systemic, nutritional, 
or chromosomal abnormalities. It can be considered 
as part of the ongoing process that is limited between 
GHD and normality, covering different degrees of GH 
secretion and responsiveness (17,18). Although, ISS 
definition might include GH peak greater than 10 ng/
mL (8), in our study we selected a particular subgroup 
that we called PGHIS that did not include children 
with GH peak between 10 and 18 ng/mL. PGHIS is 
defined as a variant of the GH insensitivity syndrome 
(Laron syndrome), characterized by a smaller reduction 
in stature, without facial abnormalities and with IGF-I 
concentrations near the lower limit of normality. In the-
ory, PGHIS can be overcome by an exogenous adminis-
tration of GH (8,11,19,20). Therefore, in these patients, 
the classic IGF-I generation test is not useful (19). 
Heterozygous mutations in the GH receptor or 
post-signaling defects may be the cause of stature 
reduction in PGHIS (21,22). As molecular screening 
is restricted to a few centers, our data suggest that the 
hormonal PGHIS diagnosis can be sufficient for the 
indication to treatment with GH. The data also show 
that short children with GH peak ≥ 18 ng/mL and 
IGF-I levels below the mean may benefit from rhGH 
treatment. Furthermore, GH therapy in children with 
PGHIS may have consequences beyond the height, 
considering that these children have more fat (18), 
probably due to impairment of lipolytic and anabolic 
actions of GH (23-26). 
The response to GH therapy with titrated doses to 
keep IGF-I in normal range, was similar in SGHD and 
MGHD. The difference between MPH and present 
height reinforce this finding. Based on experience 
and considerable research since the 1980s, the SGHD 
group would be expected to have a higher height 
response to replacement doses of GH. Our data suggest 
a superposition of height response between children 
with GH peak less than 5 ng/mL and children with 
the GH peak between 5-10 ng/mL with the schedule 
of treatment used. Whereas the majority of children 
with GH deficiency should be located in this last group 
(27), it seems exaggerated the requirement of the 
cutoff value of 5 ng/mL for treatment. It is possible 
that GH secretion in the range 5-10 ng/mL is enough 
in children with normal height and perfect GH-IGF-I 
axis, but not in short children with abnormalities in this 
axis (8). 
Our MGHD group increased their SDS height in 
the first year by 0.5, but this was not observed in the 
PGHIS group. The lower increase in height SDS in 
PGHIS may be consequent to the lower increase in 
IGF-I. Approximately one third of children with GH 
deficiency or ISS fail to increase the SDS height by 0.5 
during the first year of treatment (8,28), suggesting 
that they require higher dose of GH to surpass any 
GH in mild GHD or partial GH-IGF insensitivity
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possible partial GH or IGF-I insensitivity. This finding 
indicates that GH dose in PGHIS should be titrated to 
keep IGF-I SDS in the upper range of normality, ideally 
around +2, as suggested by Cohen and cols. (8). This 
author compared two groups of prepubertal children 
with subnormal IGF-I: GHD (peak GH less than 7 
ng/mL) and ISS (peak GH greater than 7 ng/mL). 
In the ISS, the strategy to keep SDS IGF-I around +2 
required higher doses of GH (median 65 and 119 mg/
kg/day, respectively), suggesting partial PGHIS in the 
second group. An increase of 0.3 to 0.5 SDS in height 
has been considered a successful first year response to 
GH therapy in ISS children, although this response is 
highly variable and dose dependent (5). Our cutoff 
of 18 ng/mL surely selected individuals with higher 
probability of expressing some degree of PGHIS in this 
spectrum of patients. It is important to point out that 
this group may include some patients with partial IGF-I 
insensitivity. This does not invalidate our findings, since 
these patients would also benefit from the higher IGF-I 
levels provided by the GH therapy with a more intense 
saturation of the IGF-I receptors. 
Safety profile was not assessed in this study, as 
it demands several years after GH discontinuation. 
Nevertheless, GH treatment seems to be safe and the 
concept of individualization of therapy increasingly 
expands (8,12,27,29-34). Despite the controversy of 
the French (35) arm, with 30% increased risk of death 
with GH doses higher than 50 µcg/kg/day, which was 
not observed in the Dutch, Belgian, and Swedish (36) 
arm of the “Santé Adulte GH Enfant (SAGhE)”, FDA 
believes that the benefits of continuing GH therapy 
outweighs the potential risk (37).   
Our study has some features driven from the real 
world in which was done. One such characteristic is the 
more advanced pubertal stage in the PGHIS group. As 
the increase in final height in ISS is mainly due to the 
prepubertal growth and it is correlated with the growth 
velocity in the first year of treatment (38,27), the larger 
proportion of pubertal children in PGHIS group may 
have reduced the time of growth induced by GH 
therapy in these children. Pubertal status can influence 
the GH treatment response by reducing the duration 
of treatment, the most relevant co-factor to the height 
effect, in our analysis. We must also consider that a degree 
of IGF insensitivity may be present in some patients 
from this group, making us wonder if higher IGF-I 
levels would be necessary to reach the same outcome 
observed in the MGHD and SGHD groups. But in real 
world, while SGHD children are easily diagnosed, the 
diagnosis of PGHIS is usually delayed as physicians wait 
for a possible catch-up that eventually does not occur. 
As the duration of GH treatment mostly influenced 
height gain, physicians may synchronize duration of 
treatment with tempo of growth. 
 A limitation of this study was not having included 
control groups of normal or ISS children without 
treatment. A comparison with normal children by 
expressing data as SDS for sex and chronological age 
was made in order to minimize this problem. Another 
possible criticism to our data could be a small number 
of subjects recruited, due to our strict exclusion criteria 
in patients of the public health service, reducing the 
statistical power to reveal subtle differences. Anyway, 
this paper reports the largest number of PIGHS 
individuals treated with GH published so far. A third 
limitation was the criterion of inclusion, using serum 
IGF-I concentration below the mean for chronological 
age and gender. We adapted it to short children with low 
height velocity, from the last international consensus in 
which, in a short patient with normal height velocity, 
plasma IGF-I level above the mean for age and gender 
would not require GH testing (5).
 In conclusion, the results seem to indicate that 
PGHIS and MGHD can benefit from GH therapy. 
Maybe a higher GH replacement dose is necessary in 
PIGHIS to reach the same height gain, as a higher 
increase in IGF-I levels seems to be related with a 
better outcome. Further studies may assess the efficacy 
and safety of this of this approach. 
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